版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
腹透病人營(yíng)養(yǎng)不良的管理演示文稿當(dāng)前第1頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)(優(yōu)選)腹透病人營(yíng)養(yǎng)不良的管理當(dāng)前第2頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)全面的營(yíng)養(yǎng)評(píng)估項(xiàng)目飲食調(diào)查飲食蛋白質(zhì)攝入與代謝平衡熱量的攝入與消耗平衡主觀(guān)綜合性營(yíng)養(yǎng)評(píng)估(SGA)人體測(cè)量握力試驗(yàn)生物電阻抗生化檢查當(dāng)前第3頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)營(yíng)養(yǎng)管理流程-CQI
飲食記錄飲食和治療調(diào)整飲食和營(yíng)養(yǎng)知識(shí)核對(duì)飲食反饋給病人教育食譜分析營(yíng)養(yǎng)評(píng)估當(dāng)前第4頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)營(yíng)養(yǎng)不良的管理方法當(dāng)前第5頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)HighprevalenceofmalnutritioninPDpopulationPrevalenceofmalnutrition(%)WangDongetal,2002當(dāng)前第6頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)Jun,2001-Jan,2002,多中心橫斷面BJ,90ptsResidualrenalfunctionUremictoxinsEndocrineabnormalitiesAminoacidabnormalitiesAcidosisRenaldiseaseperseDialysateendotoxinsGraftandfistulainfectionsDialysisadequacyBioincompatibilityNutrientlosses(dialysate)DialysisprocedureInfection/InflammationCongestiveheartfailureVasculardiseaseDiabetesmellitusDepressionOthercomorbidity
Co-morbidityAgeGenderGeneticsDrugs(corticosteroids)SocialfactorsOtherfactorsProteinintakeEnergyintakeVitaminintakeIntake當(dāng)前第7頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
LogisticAnalysisinACross-section
Studyin90CAPDPatientsin2002MalnutritionDPIDEITccrDMRRFLongtimeonPDCVDCRP董捷等。中華醫(yī)學(xué)雜志2003當(dāng)前第8頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)RRFinevitablylostafter2-3yrsHIDAKA,etal.NEPHROLOGY2003;8:184–191InitiationofPDGFR(mL/min/1.73m2)06121824303642Time(months)
Jan,2002-Jun,2002思考和假想當(dāng)前第9頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)FentonSA,etal,AmJKidneyDis,1997;30:334-342CAPD/CCPD與HD患者的生存率比較(1990-94)隨訪(fǎng)月30405060708090061218243036424854100CAPDHD生存率%當(dāng)前第10頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)腹透病人水和溶質(zhì)的清除Chengetal.ClinNephrol2006當(dāng)前第11頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)GroupI:TotalKt/V>1.7,residualGFR>0.5ml/minper1.73m2GroupII:TotalKt/V>1.7,residualGFR<0.5ml/minper1.73m2GroupIII:TotalKt/V<1.7,residualGFR<0.5ml/minper1.73m2JAmSocNephrol12:2450-2457,2001RRF和透析充分性低的CAPD患者每日平均蛋白攝入和熱量攝入均低RRF與營(yíng)養(yǎng)不良當(dāng)前第12頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)AY-MWang,KI,2006當(dāng)前第13頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)對(duì)腹透病人實(shí)施綜合營(yíng)養(yǎng)管理措施,包括殘余腎功能正在丟失和已經(jīng)丟失的病人主要涉及水、小分子溶質(zhì)平衡和蛋白質(zhì)能量攝入可操作性強(qiáng)
Jun,2002-now預(yù)防營(yíng)養(yǎng)不良的綜合策略當(dāng)前第14頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)策略一:穩(wěn)定的營(yíng)養(yǎng)攝入2003DOQIGuidelineDPI
1.2-1.3g/kg/d
(50%ofhighbiologicvalue)DEI30-35kcal/kg/d當(dāng)前第15頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)腹膜透析患者實(shí)際飲食蛋白攝入量普遍低于推薦值YearNo.ofPatientsDPI(g/kg/day)Wangetal.20032661.11Suttonetal.2001340.90Parketal.1999501.12Jacobetal.1995571.13Nolphetal.1993710.84Pollocketal.1990351.04當(dāng)前第16頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)(n=47)隨訪(fǎng)開(kāi)始隨訪(fǎng)結(jié)束Group1Group2Group3Group1Group2Group3營(yíng)養(yǎng)不良發(fā)生率50%50%58.8%25%33.3%41.2%隨訪(fǎng)期間總的營(yíng)養(yǎng)不良發(fā)生率由53%下降至34%(P<0.05)2002.122003.12TotalXinkuiT,JieD,TaoWetal.JRenalNutri2003當(dāng)前第17頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)我們實(shí)施的營(yíng)養(yǎng)攝入標(biāo)準(zhǔn)DPI
0.8-1.2g/kg/d
(50%ofhighbiologicvalue)DEI30-35kcal/kg/d當(dāng)前第18頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)實(shí)施技巧飲食調(diào)整蛋白質(zhì)結(jié)構(gòu)調(diào)整,量>質(zhì)喜好食物調(diào)查及食品交換份
及早添加各種口服營(yíng)養(yǎng)制劑保證透析充分性糾正合并癥減少藥物副作用當(dāng)前第19頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
策略二:小分子溶質(zhì)清除充分當(dāng)前第20頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)Adequacy:TheKDOQIRecommendations2001Guideline15:ForCAPD,thedeliveredPDdoseshouldbeatotalKt/Vofatleast2.0perweekandatotalcreatinineclearanceofatleast60L/wk/1.73m2forH&HAtransportersand50L/wkinLandLAtransporters
AJKD2001;37(Suppl1):S84當(dāng)前第21頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)ADEMEX研究2002:NO965個(gè)腹透病人隨機(jī)對(duì)照研究對(duì)照組:傳統(tǒng)的4*2L/天CAPD實(shí)驗(yàn)組:增加劑量使Ccr在60L/周,Kt/V在2.0生存情況:1年及2年生存率無(wú)差別當(dāng)前第22頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)新的閾值(目標(biāo)值)
溶質(zhì)
CAPDKt/V≥1.7(EvidencelevelA)
水分無(wú)目標(biāo)值,容量平衡
WkLoetal.ISPDGuidelines/Recommendations.PDI2006當(dāng)前第23頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)Timedependentmultivariateanalysisofsmallsolutetransportonpatientssurvivalinanuricpatients(NECOSAD)ParemerterCutoffpointsRelativeriskP-valueKt/V(l/w)>=1.7<1.7<1.511.473.280.310.02Ccr(l/w)>=45<45<4011.373.260.460.02JansenMAMetal.KidneyInt,2005當(dāng)前第24頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)小分子溶質(zhì)清除充分嗎?
BasedonDPIlevelKt/V>=1.5BUN:20-25mmol/l
沒(méi)有尿毒癥癥狀
Kt/VDPI氮平衡Kt/V當(dāng)前第25頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
溶質(zhì)清除總清除
液體清除殘腎清除透析時(shí)間透析時(shí)間殘腎清除腹膜清除腹膜清除總清除
策略三:容量平衡
當(dāng)前第26頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)腹膜透析水與溶質(zhì)清除的變化時(shí)間(年)水容量(ml)總清除腹膜清除殘腎清除容量負(fù)荷蜜月期
動(dòng)蕩期
穩(wěn)定或惡化期當(dāng)前第27頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)策略三:容量平衡水份攝入約1-1.5L/d,攝鹽6g利尿劑平均增加尿量100-200ml,不保護(hù)殘腎適當(dāng)選用高濃度透析液(協(xié)議護(hù)理)新型透析液(葡聚糖透析液)
體表無(wú)水腫服兩種或以下降壓藥,BP<140/90mmHgBIA,DEXA細(xì)胞外液/總體水穩(wěn)定當(dāng)前第28頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
實(shí)施綜合的營(yíng)養(yǎng)管理策略,使得殘腎丟失過(guò)程中病人營(yíng)養(yǎng)狀況保持穩(wěn)定。董捷,王海燕。中華內(nèi)科雜志,2007,第1期營(yíng)養(yǎng)管理成效一當(dāng)前第29頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)病例選擇和方法
June,2002June,200371CAPDpatientsn=4n=9n=43
n=15June,200543CAPDpatients
HDRT
PDDeath當(dāng)前第30頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
RenalanddialyticKt/VandCcrin43CAPDpatientsduring2-yrfollow-upTime(mon)NpKt/VrKt/V
TKt/VpCcr(ml/min/1.73m2)rCcr(ml/min/1.73m2)TCcr(ml/min/1.73m2)6121824434343431.18±0.481.19±1.191.12±0.471.29±0.401.14±0.620.67±0.630.55±0.540.45±0.46*2.25±0.741.87±0.641.65±0.491.77±0.39*32.80±15.1836.17±15.6536.16±16.3841.05±13.5044.02±71.5844.15±75.5534.98±56.1625.51±28.12*76.82±64.2880.04±72.3170.13±38.9765.75±22.44
Repeated-ANOVAanalysisshowedsignificantdifferencesinrKt/V,TKt/VandrCcramong6,12,18and24monthsafterdialysis(*P=0.02)當(dāng)前第31頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)血白蛋白水平上升3333.53434.53535.53636.53737.53806121824時(shí)間P=0.0134.53±5.1035.08±4.7136.08±4.3437.30±4.5437.01±4.3938(g/l)37.53736.53635.53534.53433.533Fig1Serumalbuminlevelsin43CAPDpatientsduring2-yearfollow-up(month)當(dāng)前第32頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)營(yíng)養(yǎng)不良發(fā)生率下降0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%80.00%06121824時(shí)間16(37.2%)28(65.1%)12(27.9%)10(23.3%)11(25.6%)P=0.0180%70%60%50%40%30%20%10%0%Fig2Theprevalenceofmalnutritionin43CAPDpatientsduring2-yearfollow-up(month)當(dāng)前第33頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
Time(mon)NDPI(g/kg/d)DEI(kcal/kg/d)CRP(mg/L)CO2CP(mmol/l)ECW/TBWnECW6121824434343430.92±0.420.92±0.290.88±0.290.87±0.2229.32±11.428.49±8.127.52±6.7228.12±6.981.38±1.564.60±3.913.76±3.805.04±3.7225.17±3.5626.50±2.7024.58±1.5926.05±2.660.50±0.040.52±0.120.49±0.050.50±0.050.23±0.030.23±0.020.23±0.010.22±0.02
Associatedfactorsofmalnutritionin43CAPDpatientsduring2-yrfollow-upRepeated-ANOVAanalysisshowednodifferenceinDPI,DEI,CRP,CO2CP,ECW/TBW,nECWamong6,12,18and24monthsafterdialysis(P>0.05)當(dāng)前第34頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)
實(shí)施綜合的營(yíng)養(yǎng)管理策略,使得殘腎已經(jīng)丟失的腹透病人營(yíng)養(yǎng)狀況保持穩(wěn)定。DongJ,WangHY.Unpublisheddata.營(yíng)養(yǎng)管理成效二當(dāng)前第35頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)病例選擇和方法
June,200455CAPDpatientsn=4n=2n=35
n=14June,200635CAPDpatients
HDRT
PDDeath當(dāng)前第36頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)BaselinelevelsofnutritionalindexesinoliguricandanuricCAPDpatientswithDPI≥0.75g/kg/dand<0.75g/kg/d(n=55)VariablesPatientswithDPI≥0.75g/kg/d(n=41)PatientswithDPI<0.75g/kg/d(n=14)P(torχ2)DPI(g/kg/d)DEI(kcal/kg/d)Alb(g/l)BUN(mmol/l)Scr(umol/l)LBM(kg)Prevalenceofmalnutrition#(n,%)1.02±0.1832.35±5.6337.45±2.8821.76±6.56859.02±203.6741.63±10.0512(29.26%)0.63±0.12*24.87±6.38*34.72±3.81*21.36±7.63835.42±190.6738.38±4.305(35.71%)0.0000.0000.0080.7130.8530.1180.908當(dāng)前第37頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)P=0.017P=0.0176月后兩組DPI水平趨于一致當(dāng)前第38頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)P=0.0296月后兩組DEI水平趨于一致當(dāng)前第39頁(yè)\共有45頁(yè)\編于星期五\12點(diǎn)少尿和無(wú)尿腹透病人透析充分性和容量控制均保持穩(wěn)定
DPI≥0.75g/kg/d(group1)和DPI<0.75g/kg/d(group2)on0,6,12,18,24月Indexes0months(n=55)6months(n=47)12months(n=39)18months(n=36)24months(n=35)P(F)P(F#)Kt/VGoup1Group2Tccr(l/w/1.73m2)Goup1Group2nECW(kg/height)Goup1Group2ECW/TBWGoup1Group2SBP(mmHg)Goup1Group2DBP(mmHg)Goup1Group2MBP(mmHg)Goup1Group2CRP(mg/l)Group1Group21.75±0.181.78±0.2356.05±12.4154.89±8.360.26±0.040.24±0.040.50±0.030.52±0.05133.89±25.48138.75±26.2078.28±13.4875.83±13.2896.82±15.1598.66±18.352.84(0.17~32.65)3.74(1.17~27.28)1.83±0.281.72±0.2458.02±13.9552.39±7.180.25±0.030.22±0.030.51±0.030.52±0.02129.51±22.66129.16±28.5173.96±9.4875.33±7.1493.23±13.7892.12±17.544.14(0.19~54.29)3.65(0.65~59.30)1.75±0.261.63±0.1657.05±11.7352.46±8.310.25±0.030.24±0.020.50±0.040.53±0.03132.21±20.04133.44±24.4174.65±12.7678.57±6.7493.81±12.9896.67±17.064.91(0.94~41.60)3.90(0.26~11.97)1.70±0.211.65±0.2052.63±12.6753.85±9.370.24±0.030.21±0.010.50±0.030.52±0.03135.20±18.83122.43±27.2072.21±11.32
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- GB/T 4996-2025平托盤(pán)試驗(yàn)方法
- 成語(yǔ)考試真題及答案
- bim應(yīng)用案例分析考試題庫(kù)及答案
- 疑難病例討論制度題庫(kù)(含答案)
- 技術(shù)研發(fā)經(jīng)理招聘筆試題及解答(某世界500強(qiáng)集團(tuán))附答案
- 人文考試試題附答案詳解
- 醫(yī)院感染知識(shí)競(jìng)賽試題(附答案)
- 裝配鉗工高級(jí)模擬試題含參考答案
- 2025年主管護(hù)師考試試題與答案
- 保險(xiǎn)公估人考試真題題庫(kù)及答案
- 石籠網(wǎng)廠(chǎng)施工技術(shù)交底
- 新建粉煤灰填埋場(chǎng)施工方案
- 2025至2030全球及中國(guó)經(jīng)顱刺激器行業(yè)產(chǎn)業(yè)運(yùn)行態(tài)勢(shì)及投資規(guī)劃深度研究報(bào)告
- 互聯(lián)網(wǎng)運(yùn)維服務(wù)保障承諾函8篇范文
- 中遠(yuǎn)海運(yùn)集團(tuán)筆試題庫(kù)2025
- 電力三種人安全培訓(xùn)課件
- 船舶生產(chǎn)許可管理辦法
- 戒毒所生產(chǎn)安全知識(shí)培訓(xùn)課件
- 江蘇省淮安市2024-2025學(xué)年七年級(jí)下學(xué)期期末歷史試題(含答案)
- 醫(yī)療質(zhì)量安全核心制度落實(shí)情況監(jiān)測(cè)指標(biāo)
- 電鍍公司車(chē)間承包協(xié)議書(shū)
評(píng)論
0/150
提交評(píng)論